Arcutis Biotherapeutics Inc (ARQT)
Who owns Arcutis Biotherapeutics Inc (ARQT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.0% of the shares are freely tradable; institutional investors hold 110.2%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.86 | 12,327,000 | +3.0 | 03/31/2026 |
| Frazier Life Sciences Management, L.P. | 7.90 | 9,874,511 | +0.0 | 03/31/2026 |
| BlackRock Inc | 7.36 | 9,200,411 | +1.1 | 03/31/2026 |
| Rubric Capital Management LP | 6.61 | 8,271,577 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 5.80 | 7,253,936 | +1.5 | 12/31/2025 |
| State Street Corp | 5.03 | 6,296,197 | +14.7 | 03/31/2026 |
| Polar Capital Holdings PLC | 4.53 | 5,666,940 | +2.0 | 03/31/2026 |
| Jennison Associates LLC | 3.98 | 4,980,770 | -26.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.89 | 4,871,536 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Polar Capital Biotech S Inc | 4.28 | 5,355,935 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Peetz Christopher | Director | Other | 4,315 | 0.00 | – |
| 15. Jul 2026 | Welgus Howard G. | Director | Sell | 4,730 | 26.91 | 127,284 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 2,255 | 8.63 | 19,461 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 1,019 | 7.51 | 7,653 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 822 | 6.52 | 5,361 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.